The Oral Advantage: New Treatment Opportunities in Psoriasis & Melasma

Abstract

Psoriasis and melasma are two prevalent dermatologic conditions with significant impact on patients\' quality of life. Traditional therapies often rely on topical or systemic modalities, yet recent advances in oral treatments have redefined management paradigms. This review critically examines the epidemiology, pathophysiology, clinical presentation, diagnosis, and evolving treatment landscape of psoriasis and melasma, with a focus on oral therapeutic strategies. Current evidence from randomized controlled trials and guideline updates is discussed to elucidate the clinical potential of novel oral agents, their mechanisms, and their role in enhancing patient care.

Introduction

Psoriasis and melasma represent distinct yet challenging dermatological disorders, each with unique etiologies, clinical spectra, and therapeutic complexities. Psoriasis is a chronic, immune-mediated inflammatory disease characterized by erythematous, scaly plaques, while melasma is a pigmentary disorder marked by symmetric hyperpigmented macules, predominantly on sun-exposed skin. Both conditions can significantly impair psychological well-being and social functioning. Despite advances in topical and procedural therapies, treatment resistance, recurrence, and patient compliance remain ongoing challenges. The emergence of novel oral therapies, including small molecule inhibitors and targeted agents, offers new hope for improved disease control and patient quality of life. This review synthesizes current evidence on the oral treatment revolution in psoriasis and melasma, providing clinicians with an up-to-date resource for evidence-based practice.

Epidemiology / Disease Burden

Psoriasis affects approximately 2-3% of the global population, with notable geographical and ethnic variability. The disease can manifest at any age but typically presents between the ages of 15 and 35. Its chronic, relapsing course is associated with considerable morbidity, including psoriatic arthritis and increased cardiovascular risk. Melasma, on the other hand, has a striking female predominance and is more prevalent in individuals with Fitzpatrick skin types III-V. Prevalence rates range from 1.5% to 33% depending on the population studied, with higher incidence in Asian, Hispanic, and Middle Eastern populations. Both conditions are associated with substantial psychosocial burden, impacting self-esteem and emotional health.

Pathophysiology

Psoriasis is driven by complex immune dysregulation, involving the interplay of genetic susceptibility and environmental triggers. Key mediators include Th17 and Th1 lymphocytes and cytokines such as TNF-α, IL-17, and IL-23, which orchestrate keratinocyte hyperproliferation and sustained inflammation. Recent advances have elucidated the pathogenic role of the IL-23/Th17 axis, paving the way for targeted oral therapies.Melasma pathogenesis is multifactorial, involving genetic predisposition, ultraviolet (UV) exposure, hormonal influences (notably estrogen and progesterone), and cutaneous inflammation. Dysregulated melanogenesis, upregulation of melanocyte-stimulating cytokines, and oxidative stress contribute to hyperpigmentation. The recognition of an inflammatory component in melasma has opened avenues for anti-inflammatory oral agents.

Risk Factors

For psoriasis, risk factors encompass family history, obesity, smoking, alcohol consumption, infections (especially streptococcal pharyngitis), and certain medications (e.g., lithium, beta blockers). Psychosocial stress and trauma (Koebner phenomenon) can also precipitate or exacerbate disease flares.Melasma risk factors include female sex, pregnancy (chloasma), oral contraceptives, hormone replacement therapy, thyroid dysfunction, UV exposure, and certain cosmetics or phototoxic drugs. Genetic susceptibility plays a pivotal role, as does chronic exposure to sunlight or heat.

Clinical Features

Psoriasis presents in several clinical subtypes, with chronic plaque psoriasis being most common, characterized by well-demarcated, erythematous plaques with silvery scales. Other variants include guttate, inverse, pustular, and erythrodermic psoriasis. Nail changes and psoriatic arthritis may co-exist, further complicating management.Melasma manifests as symmetrical, irregularly bordered, brown-to-gray macules and patches, typically on the cheeks, forehead, upper lip, and chin. The pigmentation may be epidermal, dermal, or mixed, influencing therapeutic response. Melasma is often chronic and recalcitrant, with periods of remission and relapse.

Diagnosis

Diagnosis of psoriasis is primarily clinical, supported by characteristic morphology and distribution. Skin biopsy may be warranted in atypical presentations. Assessment of disease severity (e.g., PASI score) and impact on quality of life (DLQI) guide treatment selection.Melasma diagnosis is also clinical, with Wood\'s lamp examination aiding in distinguishing epidermal from dermal pigmentation. Histopathology reveals increased melanin in basal and suprabasal keratinocytes for epidermal melasma, and dermal melanophages in deeper forms. Exclusion of other causes of hyperpigmentation, such as drug-induced or post-inflammatory, is essential.

Treatment & Management

The therapeutic goals in psoriasis include rapid control of inflammation, reduction of lesion burden, and minimization of comorbidities. Topical therapies (corticosteroids, vitamin D analogues), phototherapy, and systemic agents (methotrexate, cyclosporine, acitretin) have long constituted first-line options. Biologics targeting TNF-α, IL-17, and IL-23 have revolutionized moderate-to-severe disease management.Melasma management centers on photoprotection and topical depigmenting agents (hydroquinone, azelaic acid, retinoids). Chemical peels and laser therapies provide adjunctive benefit. Systemic therapies such as tranexamic acid have gained prominence for refractory cases, especially where topical agents fail to achieve satisfactory results.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of small molecule oral agents that target key pathogenic pathways in both psoriasis and melasma.For psoriasis, oral phosphodiesterase-4 (PDE4) inhibitor apremilast and the TYK2 inhibitor deucravacitinib offer non-biologic alternatives with favorable safety profiles. Apremilast modulates multiple inflammatory mediators, while deucravacitinib selectively inhibits TYK2, a key regulator of IL-23 and type I interferon signaling. Both agents demonstrate efficacy in moderate-to-severe psoriasis, with improvements in PASI scores and patient-reported outcomes.In melasma, oral tranexamic acid (TXA) has emerged as a promising adjunct, inhibiting plasminogen activation and reducing UV-induced melanogenesis and vascular factors. Several randomized controlled trials and meta-analyses have confirmed the efficacy of TXA in reducing Melasma Area and Severity Index (MASI) scores, with generally mild and reversible side effects. Other investigational oral agents include antioxidants (polypodium leucotomos extract, glutathione) and anti-inflammatory compounds, though large-scale studies are warranted.Importantly, the oral route of administration offers improved patient adherence, wider coverage for recalcitrant or extensive disease, and the potential for combination or stepwise approaches with topical or procedural therapies.

Guideline Recommendations

Current international guidelines endorse the use of oral agents in moderate-to-severe psoriasis inadequately controlled by topical therapies or phototherapy. Apremilast and deucravacitinib are recommended as alternatives when biologics are contraindicated or not feasible, with periodic monitoring for adverse events.For melasma, the use of oral tranexamic acid is increasingly recognized in consensus statements and algorithmic guidelines, particularly for patients unresponsive to topical agents. However, careful patient selection and risk assessment are crucial, especially in those with thromboembolic risk factors. Multimodal approaches, combining oral, topical, and procedural therapies, are emphasized for optimal outcomes.

Conclusion

The advent of novel oral therapies represents a significant milestone in the management of psoriasis and melasma, offering new avenues for disease control, improved quality of life, and greater patient convenience. Mechanism-based oral agents such as apremilast, deucravacitinib, and tranexamic acid have demonstrated clinical efficacy and safety across diverse patient populations. Ongoing research into personalized medicine, biomarkers, and combination regimens promises to further refine therapeutic strategies. As the therapeutic armamentarium expands, a multidisciplinary, evidence-based approach remains paramount to maximizing benefits and minimizing risks for patients with psoriasis and melasma.